


CLAIMS

1. A compound of formula I:



5

and salts and solvates thereof, wherein:


R¹⁰ is a nitrogen protecting group and R¹¹ is either OH or O-R¹², wherein R¹² is an oxygen protecting group, or R¹⁰ and R¹¹ together form a double bond between N10 and C11;

10 and R¹⁰' and R¹¹' are selected from the same options as R¹⁰ and R¹¹ respectively.

2. A compound according to claim 1, wherein R¹⁰' and R¹¹' are the same as R¹⁰ and R¹¹ respectively.

15

3. A compound according to either claim 1 or claim 2, wherein the compounds have the following stereochemistry at the C11 position:



20 when R¹⁰ and R¹¹ do not form a double bond.

4. A compound according to any one of claims 1 to 3, wherein the nitrogen protecting groups are selected from carbamate nitrogen protecting groups.

25

5. A compound according to claim 4, wherein the nitrogen protecting groups are selected from the group consisting of Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.

6. A compound according to claim 1 or claim 2, wherein R¹⁰ and R¹¹ together form a double bond between N10 and C11.

5

7. A compound according to any one of claims 1 to 6, wherein at least 50% is in either the E-, E- or Z-, Z- forms.

8. A method of synthesising a compound of any one of claims 1
10 to 7.

9. A compound of any one of claims 1 to 7 and pharmaceutically acceptable salts and solvates thereof, for use in a method of therapy.

15

10. A pharmaceutical composition comprising a compound of any one of claims 1 to 7 and pharmaceutically acceptable salts and solvates thereof, and a pharmaceutically acceptable excipient.

20 11. The use of a compound of any one of claims 1 to 7 and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a medicament for the treatment of a gene-based disease.

25 12. A method for the treatment of a gene-based disease, comprising administering to a subject suffering from a gene-based disease a therapeutically-effective amount of a compound of any one of claims 1 to 7 or pharmaceutically acceptable salts and solvates thereof.

30

13. The use of claim 11 or the method of claim 12, wherein the gene-based disease is a proliferative disease.

35 14. The use of claim 11 or the method of claim 12, wherein the gene-based disease is infection by gram-positive bacteria.

15. The use or method of claim 14, wherein the gram-positive bacteria is selected from MRSA and VRE.